Sisram MedicalSRAMF 49 Return-on-Tangible-Asset is 6.62% as of Dec. 2025, which is 20% below its 10-year median of 8.32. GuruFocus rates SRAMF with a GF Score™ of 49/100 and a GF Value™ of $0.98 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Sisram Medical ranks better than 66.16% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sisram Medical's annualizedNet Income for the quarter that ended in Dec. 2025 was $25.2 Mil. Sisram Medical's average total tangible assets for the quarter that ended in Dec. 2025 was $380.5 Mil. Therefore, Sisram Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 6.62%.
The historical rank and industry rank for Sisram Medical's Return-on-Tangible-Asset or its related term are showing as below:
SRAMF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.06 Med: 8.32 Max: 12.24
Current: 5.1
During the past 12 years, Sisram Medical's highest Return-on-Tangible-Asset was 12.24%. The lowest was 5.06%. And the median was 8.32%.
SRAMF's Return-on-Tangible-Asset is ranked better than 66.16% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs SRAMF: 5.10
Sisram Medical (OTCPK:SRAMF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sisram Medical Return-on-Tangible-Asset Related Terms
Sisram Medical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sisram Medical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRAMF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Sisram Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sisram Medical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 6.62% mean?
Sisram Medical (SRAMF) has a Return-on-Tangible-Asset of 6.62% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sisram Medical and its competitors. This is 20% below median its historical median of 8.32. Over the past decade, Sisram Medical's Return-on-Tangible-Asset has ranged from 5.06 to 12.24. According to the industry distribution chart, Sisram Medical ranks #289 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 33.8%.
Is Sisram Medical's Return-on-Tangible-Asset too high?
Sisram Medical's current Return-on-Tangible-Asset of 6.62% is 20% below median its 10-year median of 8.32. Over the past 10 years, this metric has ranged from a low of 5.06 to a high of 12.24. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Sisram Medical's value of 6.62% is 1012.6% above this industry median. Based on the distribution chart, Sisram Medical ranks #289 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sisram Medical has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #289 out of 854 companies for Return-on-Tangible-Asset. This puts Sisram Medical in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. Sisram Medical's value of 6.62% is 1012.6% above this benchmark. Historically, Sisram Medical's own Return-on-Tangible-Asset has ranged from 5.06 to 12.24 over the past decade. While the company's 10-year median is 8.32 vs. the industry median of 0.60, Sisram Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current Return-on-Tangible-Asset of 6.62% is 1012.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current Return-on-Tangible-Asset is 6.62%, which is 20% below median its own 10-year median of 8.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.98, compared to a current price of $0.44 — trading 55.3% below its estimated fair value. The current Return-on-Tangible-Asset is 6.62%, which is 20% below median its 10-year median of 8.32 and 1012.6% above the Medical Devices & Instruments industry median of 0.60. Sisram Medical's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Return-on-Tangible-Asset is 6.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 55.3% below its estimated GF Value™ of $0.98.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
Return-on-Tangible-Asset: 6.62% (20% below median its 10-year median of 8.32)
GF Value™: $0.98 vs. price of $0.44 (55.3% below fair value)
Industry Position: 1012.6% above the Medical Devices & Instruments median (#289 of 854)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
49GF Score
Get the complete analysis for SRAMF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
